OrbiMed nets $4.5B across 3 funds, ready to shower budding biopharmas with fresh capital

OrbiMed, one of the biggest global financers of private and public biopharmas, has brought in […]

OrbiMed, one of the biggest global financers of private and public biopharmas, has brought in $4.3 billion to shower on new healthcare and life sciences startups in the coming years. 

The latest haul, announced Tuesday, is the cumulative amount raised between three different funds: Private Investments, Asia Partners and Royalty & Credit Opportunities. Carter Neild, a managing partner at the firm, said that the Asia Partners fundraise was relatively similar to the amount raised in March 2021 when the last fund closed. But the other two grew “30%, 35%, or more,” he said. The net $4.3 billion sum is 23% larger than the $3.5 billion closed in March 2021 across three predecessor funds. 

“What we always try to be careful on is that the fund size we’re selecting matches the opportunity set,” said Neild. “And the opportunity set has been growing based on things like increasing innovation [and] increasing demand for non-equity funding.” 

Original article: (https://www.fiercebiotech.com/biotech/orbimed-nets-45-billion-latest-fund-ready-shower-budding-biopharmas-fresh-capital)